Safety Evaluation of Intracoronary Infusion of Extracellular Vesicles in Patients Following Coronary Stent Implantation

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 2, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Percutaneous Coronary Intervention
Interventions
DRUG

PEP

A biological drug made of certain parts of blood from living blood donors obtained from a certified blood bank. At the time of cardiac catheterization patients will undergo one-time intracoronary infusion of 10 milliliters of PEP dosage consisting of approximately 5%, 10%, or 20% PEP. PEP dose will be infused immediately distal to the newly placed stent over approximately 5 minutes.

Trial Locations (1)

55905

Mayo Clinic, Rochester

All Listed Sponsors
collaborator

Rion LLC

UNKNOWN

lead

Christopher J. McLeod

OTHER

NCT04327635 - Safety Evaluation of Intracoronary Infusion of Extracellular Vesicles in Patients Following Coronary Stent Implantation | Biotech Hunter | Biotech Hunter